Wei Li, Ph.D. | Acting Chief Executive Officer
Prior to joining WuXi Healthcare Ventures, Dr. Li focused his effort on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partner Asia, and Baird Venture Partners. He also led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, a biotech company in Boston, MA. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and the Journal of Biological Chemistry. Wei received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing.
Feng Cao, Ph.D. | Chief Operating Officer
Dr. Cao joins AltheaDx with over fifteen years of experience in the molecular diagnostics space. Before expanding to lead Operations, Dr. Cao was AltheaDx’s VP of Software Development and Informatics, where he was responsible for the combined use of genetics, algorithm, and analytics to improve our IDgenetix® tests. Prior to joining AltheaDx, Dr. Cao held management positions at Hologic and Third Wave Technologies where he launched the Invader Call Reporter® software for molecular diagnostic IVD tests. Dr. Cao earned his doctorate in Cell Biology from Medical College of Wisconsin, his master’s degree in Computer Science from Marquette University, and his bachelor’s degree in Biology from Peking University.
Alejandra Maciel | Clinical Affairs
With over twelve years of experience in the diagnostic and medical device industries, Ms. Maciel brings her expertise in clinical trial design and management to AltheaDx. As head of Clinical Affairs at AltheaDx, she is responsible for developing and implementing AltheaDx’s clinical strategy, collaborating with subject matter experts and working with commercial and government payers to establish coverage and reimbursement for AltheaDx’s products. Ms Maciel joined AltheaDx in 2015 and led the design, implementation and publication of the then largest randomized clinical trial in pharmacogenetics for depression. Prior to joining AltheaDx, Ms. Maciel served as the Clinical & Regulatory Manager at Nexus-Dx, leading the overall clinical and regulatory strategy for point of care diagnostic products. Ms. Maciel has also held key positions at Quidel, Gen-Probe (Hologic) and Nanogen. She earned a B.S in Evolutionary Biology from University of California, San Diego and is currently completing a Master’s in Advanced Studies of Clinical Research at UCSD.